We describe the prevalence of diabetes and the parameters indicative of an adequate diabetes care according the recommended international standards. RESULTS: 147 (47%) out of the 312 patients were patients with diagnosis of diabetes.There were no differences between the
DM (n=147) and non-DM group (n=165) with respect to arterial hypertension (62% vs 53%) and chronic renal failure (14%vs18%) prevalences. Dyslip-idemia (44%DM-group vs 21% selleck products no-DM group,p=<0.01) and cardiovascular disease (20% vs 9%,p=0.03) occurred more frequently in the DM-group. 69% of diabetic patients were obese/ overweight and 85% had abdominal obesity. With regards to diabetic care based on accepted international standards, it included drug therapy (insulin in 54%, oral antidiabetic
drugs in 39.5%), exercise (moderate in 33%), diabetic diet (62)%, and diabetic management education (40%). However, hemoglobin A1c levels were adequately controlled in only 27% of patients. A free diet was followed by 36% of the patients, and a sedentary life and/ or light Daporinad in vitro physical exercise was practised by 65%. Moreover, screening for complications of diabetes had never been performed in 50% of patients in terms of ret-inopathy, nephropathy and cardiovascular disease., and less than 10% had been screened for neuropathy and diabetic foot. CONCLUSIONS: 1.Prevalence of diabetes and common diabetes-associated conditions in LTR are high;2.Control of DM in LTR is poor,with low control of risk factors associated withD-M,a poor screening of DM complications and poor glycemic control;3.Treatment is focused on the use of antidiabetic drugs disregarding other treatments,such as exercise and diet;4.The role of the LT team is important to improve control of DM but ultimately a multidisciplinary approach is required. Disclosures:
José Ignacio Herrero – Speaking and Teaching: Roche, Astellas, Novartis; Stock Shareholder: Roche, Novartis, Abbott, GlaxoSmitthKline Martin Prieto – Advisory Committees or Review Panels: Bristol, Gilead The following people have PAK5 nothing to disclose: Beatriz Rodríguez-Medina, Diego Alvarez de Sotomayor, Carla Satorres, Trinidad Serrano, Manuel De la Mata, Carmen Vinaixa, Victoria Aguilera, Angel Rubin, Marina Berenguer BACKGROUND: Over the past decade, cardiovascular disease has emerged as a major cause of long-term complications after liver transplantation (LT). However, little is known about early major adverse cardiac events (MACE) following transplant. AIM: To determine the cumulative risk and predictive factors for early (30-day and 1-year) MACE after LT. METHODS: We identified all adult recipients of a first LT at our institution from 2/2002-12/2012.